Literature DB >> 32215658

Something old, something new: a paradigm for considering immune therapies for cardiovascular disease.

Brittany N Weber1, Ron Blankstein1.   

Abstract

Entities:  

Keywords:  Colchicine; Coronary artery disease; Inflammation

Mesh：

Substances：

Year:  2020        PMID： 32215658      PMCID： PMC7828463          DOI： 10.1093/cvr/cvaa055

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  8 in total

1.  The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.

Authors:  Stefan M Nidorf; Aernoud T L Fiolet; John W Eikelboom; Astrid Schut; Tjerk S J Opstal; Willem A Bax; Charley A Budgeon; Jan G P Tijssen; Arend Mosterd; Jan H Cornel; Peter L Thompson
Journal:  Am Heart J       Date:  2019-10-20       Impact factor: 4.749

2.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

3.  Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population.

Authors:  Aaron S Kesselheim; Jessica M Franklin; Seoyoung C Kim; John D Seeger; Daniel H Solomon
Journal:  J Gen Intern Med       Date:  2015-04-09       Impact factor: 5.128

4.  Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.

Authors:  Paul M Ridker; Brendan M Everett; Aruna Pradhan; Jean G MacFadyen; Daniel H Solomon; Elaine Zaharris; Virak Mam; Ahmed Hasan; Yves Rosenberg; Erin Iturriaga; Milan Gupta; Michelle Tsigoulis; Subodh Verma; Michael Clearfield; Peter Libby; Samuel Z Goldhaber; Roger Seagle; Cyril Ofori; Mohammad Saklayen; Samuel Butman; Narendra Singh; Michel Le May; Olivier Bertrand; James Johnston; Nina P Paynter; Robert J Glynn
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

5.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.

Authors:  Jean-Claude Tardif; Simon Kouz; David D Waters; Olivier F Bertrand; Rafael Diaz; Aldo P Maggioni; Fausto J Pinto; Reda Ibrahim; Habib Gamra; Ghassan S Kiwan; Colin Berry; José López-Sendón; Petr Ostadal; Wolfgang Koenig; Denis Angoulvant; Jean C Grégoire; Marc-André Lavoie; Marie-Pierre Dubé; David Rhainds; Mylène Provencher; Lucie Blondeau; Andreas Orfanos; Philippe L L'Allier; Marie-Claude Guertin; François Roubille
Journal:  N Engl J Med       Date:  2019-11-16       Impact factor: 91.245

Review 6.  Colchicine in Pericardial Disease: from the Underlying Biology and Clinical Benefits to the Drug-Drug Interactions in Cardiovascular Medicine.

Authors:  Aldo L Schenone; Venu Menon
Journal:  Curr Cardiol Rep       Date:  2018-06-14       Impact factor: 2.931

Review 7.  Colchicine: its mechanism of action and efficacy in crystal-induced inflammation.

Authors:  George Nuki
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

8.  Low-dose colchicine for secondary prevention of cardiovascular disease.

Authors:  Stefan M Nidorf; John W Eikelboom; Charley A Budgeon; Peter L Thompson
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.